GSK805 was demonstrated to be effective in suppression of Th17 cell differentiation via antagonizing RORγt26, while XY018 was shown to strongly inhibit the growth of androgen receptor-positive prostate tumors via inhibition of tumor cell RORγ27. The gene discussed is AR; the disease is prostate neoplasm.